RESULTS: The most common adverse events are cough, wheezing, lower respiratory infection and atelectasis (24.1%, 13.8%, 10.3%, 10.3%, repectively). Data from 6-mon daily recordingsdiaries collected for 6 mon indicated significant improvements under baseline in frequency of acute exacerbations (p=0.027), variation of PEF (p=0.008), dose of ICS (p=0.02) and, dose of OCS (p=0.037). Compared to baseline, miniAQLQ scores (6.4±0.5vs.5.2±0.9, p=0.031) and symptom-free days (21.2±7.2vs.14.5±3.7, p=0.05) were significantly improved at 6 mon. All abovethe measurements above were improved at 12 mon. ACQ-6 scores, ACT scores, PEF values and spirometry measurements remained stable throughout the study period.